BKT140

07/01/2013 - "In vitro efficacy of BKT140 alone or in combination with rituximab was determined in non-Hodgkin lymphoma (NHL) cell lines and primary samples from bone marrow aspirates of patients with NHL. "
07/01/2013 - "Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140."

11/01/2012 - "In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer."

01/15/2014 - "The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma."
03/01/2011 - "BKT140 significantly and preferentially stimulated multiple myeloma apoptotic cell death. "
03/01/2011 - "In vivo, subcutaneous injections of BKT140 significantly reduced, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts. "
03/01/2011 - "Taken together, these results suggest a potential therapeutic use for BKT140 in multiple myeloma and leukemia patients."
09/01/2012 - "Among these, AMD3100, also known as Plerixaform (Mozobil by Genzyme), is approved for stem cell mobilisation in patients with leukaemia, while BKT140 (Emory University), POL6326 (Polyphor Ag) and TG-0054 (ChemoCentryx) are currently in clinical trials in combination with chemotherapy for multiple myeloma and leukaemia. "

04/05/2022 - "Plerixafor, BKT140, LY2510924, PF-06747143, ulocuplumab, and NOX-A12 are among the most well-known CXCR4 and CXCL12 modulators that their therapeutic efficacies have been evaluated in different pre-clinical and clinical studies of hematologic malignancies. "

07/01/2013 - "BKT140 treatment inhibited the local tumor progression and significantly reduced the number of NHL cells in the bone marrow. "
03/01/2011 - "Tumors from animals treated with BKT140 were smaller in size and weights, had larger necrotic areas and high apoptotic scores. "
05/01/2014 - "Moreover, the combination of BKT140 with low-dose imatinib markedly inhibited tumor growth, achieving 95% suppression. "
11/01/2012 - "Targeting the CXCL12/CXCR4 axis with BKT140 attenuated NSCLC cells tumor growth and augmented the effects of chemotherapy and radiotherapy. "
04/01/2011 - "CXCR4 antagonists, such as Plerixafor (AMD3100) and T140 analogues (TN14003/BKT140), can disrupt CXCR4-mediated tumor cell adhesion to stromal cells and sensitize lung cancer cells to cytotoxic drugs. "